Left Main Coronary Atherosclerosis Progression, Constrictive Remodeling, and Clinical Events  by Puri, Rishi et al.
C
t
a
A
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 6 , N O . 1 , 2 0 1 3
© 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 2 . 0 9 . 0 0 6Left Main Coronary Atherosclerosis Progression,
Constrictive Remodeling, and Clinical Events
Rishi Puri, MBBS, Kathy Wolski, MPH, Kiyoko Uno, MD, PHD, Yu Kataoka, MD,
Karilane L. King, MS, Timothy D. Crowe, MS, Samir R. Kapadia, MD,
E. Murat Tuzcu, MD, Steven E. Nissen, MD, Stephen J. Nicholls, MBBS, PHD
Cleveland, Ohio
Objectives The aim of this study was to evaluate the progression of atherosclerosis within the left
main coronary artery (LMCA) in association with risk factor modifying therapies.
Background Despite studies demonstrating slowing of disease progression within epicardial coro-
naries with risk factor modiﬁcation, little is known about the natural history and clinical sequelae of
atherosclerosis progression within the LMCA.
Methods In 340 patients with angiographic coronary artery disease who underwent serial intravas-
cular ultrasound imaging to evaluate the effects of anti atherosclerotic therapies across 7 clinical
trials, LMCA and epicardial disease progression was characterized. Relationships between changes in
plaque burden with remodeling parameters and the incidence of major adverse cardiovascular
events (MACE) (death, myocardial infarction, hospital stay for unstable angina, and coronary revascu-
larization) were investigated.
Results Plaque regression was observed in the LMCA segment, and progression was observed in
adjacent epicardial segments (percent atheroma volume [PAV] 0.39  0.1% vs. 0.37  0.1%,
p  0.001). Changes in LMCA lumen volume correlated strongly with changes in external elastic
membrane (beta coefﬁcient 0.91, p  0.001) and negatively with the change in PAV (beta coefﬁ-
cient 0.55, p  0.001). Patients who experienced a MACE had smaller baseline LMCA minimum
lumen area (11.6 vs. 12.2 mm2, p  0.05) and greater progression of PAV in the LMCA (0.51 
0.3% vs. 0.35  0.2%, p  0.02) compared with those who were MACE-free. Signiﬁcant reductions
from baseline in both external elastic membrane (4.7  1.7 mm3, p  0.01) and lumen volumes
(4.0  1 mm3, p  0.01) were also observed in those having an event.
onclusions Left main coronary atherosclerosis responds to systemic risk factor modiﬁcation. Pa-
ients experiencing a MACE were more likely to demonstrate progressive disease and constrictive
rterial remodeling within the LMCA segment. (J Am Coll Cardiol Intv 2013;6:29–35) © 2013 by the
merican College of Cardiology Foundation
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30Culprit lesions within the left main coronary artery
(LMCA) segment might result in devastating clinical con-
sequences. Although there continues to be intense interest
in defining the most appropriate clinical revascularization
strategy for angiographically severe LMCA stenoses (1,2),
much less is known about the natural history of atheroscle-
rosis within the LMCA segment. Serial intravascular ultra-
sound (IVUS) evaluation of the epicardial coronary tree has
provided important insight into factors promoting progres-
sion of coronary atherosclerosis (3). In particular, such
studies have also demonstrated slowing of epicardial coro-
nary disease progression (4) and even regression (5) after
risk factor modification. Accordingly, the IVUS-derived
baseline plaque burden and the rate of its progression
within non-LMCA coronary segments have been shown
to be independently predictive of major adverse cardio-
vascular outcomes (6,7). Such observations, however,
including the impact of systemic risk factor modification,
have not been thoroughly investigated within the LMCA
segment.
Lumen dimensions on IVUS
(minimal lumen area and mini-
mal lumen diameter) within the
LMCA segment have been
shown to be predictive of future
coronary events (8,9). However,
the baseline extent of plaque
burden within the LMCA seg-
ment has thus far not been
shown to be an independent
predictor of coronary risk (9).
Although one might speculate
upon the importance of LMCA
arterial remodeling, mechanistic
links between serial LMCA lumen dimensions, correspond-
ing serial plaque and remodeling responses, and cardiovas-
cular outcomes have yet to be demonstrated.
The objective of the present analysis was to investigate
the serial response of the LMCA segment to systemic risk
factor modification and to compare these changes in parallel
with epicardial coronary segments in the same patient. The
association of adverse clinical events with serial plaque and
vessel responses within the LMCA segment was also
characterized.
Methods
Study population. The analysis included data from 340 of
,479 patients who participated in 7 clinical trials that
ssessed the impact of various medical therapies on changes
n coronary atherosclerosis burden with serial IVUS imaging
4,5,10–14). In each of these studies, subjects were required
o have coronary artery disease, defined as the presence of at
Abbreviations
and Acronyms
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
LMCA  left main coronary
artery
MACE  major adverse
cardiovascular events
PAV  percent atheroma
volumeeast 1 luminal narrowing of 20% angiographic stenosis int least 1 epicardial artery by a clinically indicated coronary
ngiogram. Of the 3,479 patients who underwent serial
VUS analysis in clinical trials, only those whose LMCA
egments were of sufficient length (5 mm) and image
uality at baseline and follow-up (n 340) were included in
he analysis. The corresponding adjacent epicardial seg-
ents of these 340 patients selected for LMCA analysis
ere analyzed for serial changes in plaque progression.
hese included 218 left anterior descending arteries, 116
ircumflex arteries, and 6 ramus intermedius arteries.
Acquisition and analysis of IVUS images. We previously
described in detail the acquisition and analysis of IVUS
images within the epicardial coronary tree (5,6,10–14).
Plaque burden was measured as percent atheroma volume
(PAV). Volumes occupied by the lumen and external elastic
membrane (EEM) were calculated. To directly compare the
LMCA with the longer epicardial segment, average EEM
and lumen areas over the segments were calculated. Fur-
thermore, given the overall reduced length of the LMCA
segment compared with the epicardial coronary compart-
ment, analysis was performed at 0.5-mm intervals or every
30th frame. In each of these patients, serial plaque burden
and vessel dimensions of the LMCA and corresponding
epicardial segments were characterized. The mean duration
of follow-up IVUS imaging was 21 months. Given the
variable duration of each of the clinical trials, all plaque,
vessel, and lumen values were annualized by dividing the
change in plaque burden, lumen, or EEM volumes by the
number of days between IVUS measurements and multi-
plying by 365 days (6).
Statistical analysis. Nominal data are expressed as frequency
nd percentages. Continuous data with a normal distribu-
ion are summarized with mean  SD and compared with
tudent t test. Median and interquartile range are reported
for data not having a normal distribution, and Wilcoxon-
rank sum test was used for comparisons between groups.
Categorical data were compared with chi-square test. A
generalized linear model was used to analyze the change
from baseline in atheroma burden to account for the
correlation between measurements of the LMCA and
epicardial segments within each individual. Pearson corre-
lation coefficients were used to examine the relationship
between changes in vessel dimensions and atheroma burden.
All analyses were conducted with SAS software (version 9.2,
SAS Institute, Cary, North Carolina). A p value 0.05 was
considered statistically significant.
Results
Table 1 summarizes the clinical characteristics, baseline, and
changes in average follow-up laboratory values, characteris-
tics of the LMCA segment, and information on LMCA
segment plaque progression. Patients had a mean age of
57.5 years, 35.9% were female, and there was a high
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31prevalence of cardiovascular risk factors (hypertension
77.1%, diabetes mellitus 31.5%, metabolic syndrome 58.1%,
active smokers 22.6%, prior percutaneous coronary inter-
vention 41.6%). Accordingly, a high rate of established
medical therapies was prescribed during the period of study
(statins 94.1%, aspirin 94.1%, beta-blockers 74.1%,
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers 72.6%). Changes in average follow-up
low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, and triglycerides were 14.3  37 mg/dl,
.3  13 mg/dl, and 12.3 mg/dl, respectively. No clinical
r biochemical differences were observed between patients
ho did or did not have disease progression in the LMCA
egment.
Differential serial responses of the LMCA and epicardial
segments. Table 2 summarizes the baseline and serial
changes in plaque and vessel parameters within the LMCA
and adjacent epicardial coronary segments. Table 3 de-
scribes the correlations between changes in plaque burden
and changes in lipid parameters in both the LMCA and
epicardial segments. Table 4 further describes the relation-
ships of these parameters in relation to either progression or
Table 1. Baseline Patient and Vessel Characteristics a
Parameter
All Subjects
(n  340)
Clinical parameters
Age (yrs) 57.5 9.6
Female 122 (35.9)
BMI (kg/m2) 31.9 5.9
Height (cm) 170.5 9.5
Current smoker 70 (22.6)
Hypertension 262 (77.1)
Diabetes 107 (31.5)
Prior MI 110 (32.4)
Angina pectoris 157 (50.6)
Prior CVA 14 (4.1)
Prior CABG 8 (2.6)
Prior PCI 129 (41.6)
Metabolic syndrome 197 (58.1)
Baseline lipid parameters (mg/dl)
LDL-C 103.5 37
HDL-C 43.0 13
Triglycerides 148.5 (107–217)
Changes in average follow-up
lipid parameters (mg/dl)
LDL-C 14.3 37
HDL-C 5.3 13
Triglycerides 12.3 (44–18)
Values are mean SD, n (%), or median (interquartile range). Baseline
progression versus no progression at follow-up, and baseline and cha
BMIbodymass index; CABG coronary artery bypass grafting; CV
LDL-C  low-density lipoprotein cholesterol; LMCA  left main co
intervention.regression of LMCA atherosclerosis.Compared with adjacent epicardial segments at baseline,
the LMCA had greater average atheroma area/cross-
sectional slice (6.6  2.5 mm2 vs. 4.9  2.0 mm2, p 
0.001) but smaller PAV (30.7  8.8% vs. 37.1  9.0%, p 
0.001). The baseline average LMCA lumen (14.9  4.0
mm2 vs. 8.2  2.6 mm2, p  0.001) and EEM areas/cross-
sectional slice (21.4  5.1 mm2 vs. 13.2  4.0 mm2, p 
0.001) were significantly larger than those within the
epicardial segments, respectively (Table 2). Discordant
changes in PAV were observed in the LMCA (0.39 
0.13%) and epicardial (0.37  0.13%) segments (p 
.001 for comparison). This highlights the variable arterial
emodeling response of these adjacent coronary segments.
Left main plaque regression (defined as serial change in
AV 0) was not associated with any significant change in
verage lumen (change from baseline 0.09  0.06 mm2,
 0.15) or EEM area (change in EEM from baseline of
0.03  0.08 mm2, p  0.67). By contrast, both epicardial
average lumen (change from baseline of0.38 0.06 mm2,
 0.001; p  0.001 vs. LMCA segment) and EEM
reas (change in EEM from baseline of 0.44  0.08
seline and Changes in Average Follow-Up Lipid Data
MCA Progression
(n  178)
LMCA Progression
(n  162) p Value
57.3 9.8 57.7 9.5 0.70
67 (37.6) 55 (34.0) 0.48
32.1 6.0 31.6 5.8 0.44
169.9 9.4 171.1 9.7 0.31
35 (21.5) 35 (23.8) 0.62
134 (75.3) 128 (79.0) 0.41
59 (33.1) 48 (29.6) 0.49
59 (33.1) 51 (31.5) 0.74
80 (49.1) 77 (52.4) 0.56
8 (4.5) 6 (3.7) 0.71
6 (3.7) 2 (1.4) 0.29
62 (38.0) 67 (45.6) 0.18
103 (58.2) 94 (58.0) 0.98
103.4 38 103.5 37 0.89
42.7 12 43.3 14 0.70
44.7 (111–216) 152.3 (105–217) 0.97
14.7 36 13.8 39 0.82
5.8 12 4.7 14 0.46
9.2 (40–17) 14 (47–18) 0.65
t and vessel characteristics according to left main coronary atheroma
average follow-up lipid data.
rebrovascular accident; HDL-Chigh-density lipoprotein cholesterol;
artery; MI  myocardial infarction; PCI  percutaneous coronarynd Ba
No L
1
patien
nges in
A ce
ronarymm2, p  0.001; p  0.001 vs. LMCA segment) (Table 2)
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32reduced significantly, consistent with constrictive arterial
remodeling.
In general, there was a lack of correlation between
changes in low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and triglyceride levels with changes
in plaque burden in both the LMCA and epicardial coro-
nary segments (Table 3).
Table 4 highlights that progressive LMCA disease was
associated with lower baseline PAV but similar baseline
EEM areas. In those patients who underwent plaque
progression within the LMCA segment (defined as serial
change in PAV 0), this was associated with constrictive
arterial remodeling.
Factors responsible for changes in LMCA dimensions. Table 5
ummarizes the relative contributions of vessel and plaque
imensions upon the change in lumen area in both the
Table 2. Baseline and Change in Plaque, Vessel, and Lumen Parameters
Within Left Main and Corresponding Adjacent Epicardial Coronary Segments
Parameter
Coronary Segment
(n  340)
p ValueLMCA Epicardial
Baseline
PAV 30.7 8.8 37.1 9.0 0.001
Average EEM area (mm2) 21.4 5.1 13.2 4.0 0.001
Average lumen area (mm2) 14.9 4.0 8.2 2.6 0.001
Change*
PAV 0.39 0.1 0.37 0.1 0.001
Within segment p value 0.003 0.005
Average EEM area (mm2) 0.03 0.1 0.44 0.1 0.001
Within segment p value 0.67 0.001
Average lumen area (mm2) 0.09 0.1 0.38 0.1 0.001
Within segment p value 0.15 0.001
Values are mean  SD. To enable effective comparison between the different-sized left main
coronary artery (LMCA) and neighboring epicardial segment, average areas/slice (intravascular
ultrasound frame) for atheroma area, external elastic membrane (EEM), and lumen are reported.
*Data presented as least-squares mean SE.
PAV percent atheroma volume.
Table 3. Correlations Between Changes in Plaque Burden and Lipid
Parameters Within Each Patient Stratified According to Left Main and
Epicardial Segments
Correlations Between Changes in
Plaque Burden and Lipids
Segment
LMCA Epicardial
R p Value R p Value
Change in PAV
Change in average follow-up LDL-C 0.080 0.15 0.098 0.08
Change in average follow-up HDL-C 0.043 0.43 0.079 0.15
Change in average follow-up
triglycerides
0.019 0.73 0.12 0.02
Spearman correlation coefficients.Abbreviations as in Tables 1 and 2.MCA and epicardial segments. For the LMCA segment,
he most significant factor associated with change in lumen
rea was the change in EEM area (beta coefficient  0.91,
 0.0001). Changes in PAV also correlated inversely with
he change in lumen area (beta coefficient  0.55, p 
.0001). Because all the measured vascular and plaque
arameters (lumen, vessel, and plaque areas) are inter-
elated and highly correlated with one another, a third
odel was created to ascertain the dominant influence on
umen area (Model 3, Table 5). When both the change in
laque burden and change in EEM were added together in
odel 3, the change in the EEM dimension was found to
ave the strongest correlation with the change in lumen
rea, most pronounced within the LMCA segment (stan-
ardized beta coefficient  0.83 in the LMCA segment
[p  0.001], compared with a standardized beta coefficient
f 0.73 in the epicardial segment [p  0.001]).
LMCA disease progression, remodeling, and clinical events.
Table 6 summarizes vascular factors associated with major
adverse cardiovascular events (MACE). Although no pa-
tient died during the period of study, 3 patients had
myocardial infarctions, 52 underwent coronary revascular-
ization, 1 had a stroke, and 22 were hospitalized for unstable
angina pectoris. Patients who experienced MACE had
smaller baseline LMCAminimum lumen areas (11.6 [8.2 to
14.1] mm2 vs. 12.2 [10.2 to 15.0] mm2, p  0.05), greater
baseline plaque burden (PAV: 33.6  9.1% vs. 30.2 
8.5%, p  0.01), and greater progression of atherosclerosis
PAV: 0.51  0.33% vs. 0.35  0.15%, p  0.02)
Table 4. Differences in Baseline and Changes in Plaque, Vessel, and
Lumen Parameters in Patients Who Exhibited Progressive versus
Nonprogressive Left Main Coronary Disease
Parameter
No Progression
(n  178)
Progression
(n  162) p Value
Baseline
PAV 32.8 9.3 28.3 7.5 0.001
EEM volume (mm3) 185.2 72.8 194.5 82.9 0.27
Lumen volume (mm3) 123.3 47.3 139.4 61.2 0.007
Extent of calciﬁcation* 3.2 9.1 2.5 8.3 0.37
0 (0–0) 0 (0–0) 0.37
LMCA length (mm) 8.7 3.2 9.0 3.4 0.67
Change†
PAV 1.7 0.1 1.5 0.1 0.001
Within segment p value 0.001 0.001
EEM volume (mm3) 0.5 0.9 5.9 0.9 0.001
Within segment p value 0.58 0.001
Lumen volume (mm3) 3.7 0.72 6.9 0.7 0.001
Within segment p value 0.001 0.001
Values are mean SD or median (interquartile range). *Defined as percentage of image frames
containing a90° calcific arc; length of calciumwas non-normally distributed; p value reported is
from a nonparametric test. †Data presented as least-squares mean SE.
Abbreviations as in Table 2.within the LMCA. In addition, the incidence ofMACEwas
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33coupled with greater reductions in LMCA lumen (4.0 
1.5 mm3 vs. 0.26  0.7 mm3, p  0.02) and EEM
volumes (4.74 1.7 mm3 vs.1.5 0.8 mm3, p 0.09)
ompared with those patients who were event-free. Those
atients with progressive LMCA disease (defined as serial
hange in PAV  0) experienced significantly greater
ACE rates (23.1% vs. 14.1%, p  0.04) compared with
those patients with nonprogressive LMCA disease (not
displayed in Table 6).
Discussion
Despite the profound clinical consequences of atheroscle-
rotic obstruction of the LMCA, little is known about the
natural history of atherosclerosis progression within this
Table 5. Relative Correlations of Changes in Plaque and Vessel Volumes V
Epicardial Coronary Segments
Dependent Variable: Change in
Lumen Area LMCA
Variable R2 Standardized Beta Coeffi
Model 1 Change in EEM area 0.83 0.91
Model 2 Change in PAV 0.30 0.55
Model 3 Change in EEM area 0.96 0.83
Change in PAV 0.37
Abbreviations as in Table 2.
Table 6. Association of Baseline and Changes in Atheroma and
Vessel Areas With Major Adverse Cardiovascular Events
Parameter
MACE
p ValueNo Yes
Baseline
PAV 30.2 8.45 33.6 9.1 0.01
EEM volume (mm3) 190.3 78.8 178.8 77.0 0.32
Lumen volume (mm3) 130.0 55.4 118.7 53.2 0.10
Minimum lumen area (mm2) 12.2 (10.2,15.0) 11.6 (8.2,14.1) 0.05
Changes*
PAV 0.35 0.2 0.51 0.3 0.02
Within group p value 0.023 0.13
EEM volume (mm3) 1.5 0.8 4.7 1.7 0.09
Within group p value 0.13 0.002
Lumen volume (mm3) 0.26 0.7 4.0 1.5 0.03
Within group p value 0.71 0.008
Values aremean SD. *Data are least-squares mean SE after adjusting for smoking, dyslipide-
mia, angina, and past history of PCI.
MACE  major adverse cardiac events (defined as combined endpoint of death, myocardial
infarction  revascularization and hospital stay for unstable angina); other abbreviations as in
Tables 1 and 2. All other authors have reported that they have no relationships relevant to thecontents of this paper to disclose.segment. There are no prior systematic characterizations of
serial changes of plaque and vessel topography throughout
the whole LMCA segment, and furthermore, there is a
paucity of clinical data describing the LMCA atheroscle-
rotic disease response to anti-atherosclerotic therapies. We
thus sought to undertake a comprehensive, serial volumetric
evaluation of LMCA atherosclerosis, to characterize mech-
anisms associated with LMCA atherosclerosis progression,
to compare these changes with the adjacent epicardial
coronary tree, and to furthermore evaluate factors associated
with clinical events. The major findings of this study are:
1) LMCA atherosclerosis seems to be sensitive to medical
therapies that target cardiovascular risk factors; 2) there is
significant heterogeneity between the arterial wall responses
of the LMCA segment compared with the adjacent epicar-
dial coronary tree; 3) the serial remodeling response of the
vessel wall is the strongest determinant of lumen dimensions
throughout both the LMCA and epicardial coronary tree;
and 4) patients experiencing a MACE had a greater baseline
volumetric burden of atherosclerosis and demonstrated se-
rial LMCA atheroma progression and constrictive arterial
remodeling.
Our analysis highlights the opposing serial responses of
the arterial wall to established medical therapies within the
LMCA segment, compared with the adjacent epicardial
segment. As the LMCA segment underwent overall plaque
regression, downstream epicardial segments demonstrated
net plaque progression and constrictive arterial remodeling.
These observations highlight the heterogeneous behavior of
the human coronary arterial vasculature in vivo. Although
much larger scale analyses have uncovered associations
between the baseline burden of epicardial coronary athero-
sclerosis and its rate of progression with MACE (6,15), we
found similar associations between LMCA disease progres-
sion and MACE in a much smaller sample size. These
findings demonstrate the need to further explore mecha-
nisms responsible for the development and progression of
atherosclerosis in differing vascular territories and how this
might ultimately relate to risk prediction of cardiovascular
Change in Lumen Volume of the Left Main and
Epicardial
p Value R2 Standardized Beta Coefficient p Value
0.001 0.71 0.85 0.001
0.001 0.46 0.68 0.001
0.001 0.96 0.73 0.001
0.001 0.51 0.001ersus
cientevents. It is likely that reducing the disease burden within
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34the LMCA segment might result in improved clinical
outcomes.
The paradoxical response of the LMCA segment, in
comparison with the adjacent epicardial coronary vascula-
ture, might be in part a result of the differing structural
components of the arterial wall within each segment. The
LMCA origin (ostium and proximal 2 to 4 mm of the
LMCA itself) is known to lie within the aortic wall (16). It
has thus been postulated that this section of the LMCA
might be susceptible to physiological and pathological
conditions intrinsic to the aortic wall per se. The proximal
LMCA is also known to lack surrounding adventitia, while
harboring greater amounts of smooth muscle cells and
elastic tissue, with the density of smooth muscle cells
lessening progressively down the epicardial tree (16). It is
also conceivable that differences in wall shear stress, signal
mechanotransduction, and subsequent gene splicing
pathways within the LMCA arterial wall inherently differ
in comparison with the epicardial tree. Collectively, these
structural and functional differences of the LMCA seg-
ment might provide an explanation for the differing serial
responses of these coronary segments noted in our
analysis.
Intravascular ultrasound has been used to define the
relationship between LMCA lumen dimensions with clin-
ical outcomes (8,9) and more recently to guide a clinical
revascularization strategy on the basis of a specific IVUS-
derived LMCA minimum lumen area (17). Arterial remod-
eling, in response to atherosclerotic plaque accumulation, is
considered an important determinant of vascular lumen
dimensions. Coronary arterial remodeling has also been
described as a surrogate of lesion stability, whereby the
direction of remodeling has been found to be predictive of
the nature of clinical events likely to be observed (18,19).
Prior serial evaluations of the LMCA have outlined the
importance of vessel remodeling in determining final lumen
dimension achieved over time (20–23). Our results agree
with these prior findings. We are, however, able to extend
these prior mechanistic observations and associate the oc-
currence of MACE with plaque progression and significant
reductions in LMCA EEM dimensions over time.
Prior attempts to evaluate the prognostic significance of
LMCA atherosclerosis with IVUS have been made from
static rather than serial observations in smaller series of
patients (9). Moreover, such observations have essentially
been made from isolated frames on IVUS rather than serial
volumetric analysis of plaque, lumen, and EEM measure-
ments (24,25). A series of studies that involved analysis of a
single diseased frame of the LMCA demonstrated that the
change in extent of atheroma correlated with the level of
low-density lipoprotein cholesterol and a number of vali-
dated cardiovascular risk scores (24–26). With the same
imaging methodology, correlations between the serum levels
of emerging cardiovascular risk factors (serum lipoprotein[a]and fibrinogen levels) and plaque progression within the
LMCA were also reported (27). However, difficulties in
achieving the precise degree of matching of corresponding
IVUS frames to enable true serial observations have been
well-documented (28). Instead, the matching of whole
arterial segments defined by the anatomic presence of
proximal and distal side-branches provides a greater degree
of precision for true volumetric serial analyses with IVUS
(3). Furthermore, with this approach, the correlation be-
tween individual risk factors and epicardial coronary ather-
oma volume was found to be low (29). Our observation of a
lack of correlation between established cardiovascular risk
factors as well as a lack of correlation between the serial
change in lipid parameters and progression of LMCA
disease is consistent with these prior observations made
within the epicardial coronary tree.
Several caveats with regard to the present analysis should
be noted. We selected LMCA segments of 5-mm length
to enable more accurate serial volumetric calculation of
lumen, vessel, and plaque dimensions, and this excluded
very short LMCA segments. However, most LMCA seg-
ments vary between 4 and 6 mm in length (16). Moreover,
our LMCA selection criteria coupled with IVUS measure-
ments undertaken at every 0.5-mm interval provided a more
robust technique of describing the serial behavior of LMCA
segments compared with prior published reports that used
single IVUS frames only. Given that the 340 patients
analyzed in this study were enrolled in clinical trials assess-
ing the impact of various medical therapies upon the serial
change in plaque burden, the broad implementation of
therapies designed to modulate cardiovascular risk might have
decreased the ability to further detect various other metabolic
predictors of LMCA segment plaque progression.
Given the potential dire clinical consequences of LMCA
plaque instability, characterizing the mechanisms and clin-
ical significance of the various factors involved in mediating
LMCA segment plaque progression are of considerable
interest. We show, for the first time, the overall favorable
response of the LMCA segment to various strategies of
modifying cardiovascular risk. We also provide the first
observation of patients with established MACE exhibiting
greater degrees of baseline LMCA plaque burden, serial
plaque progression, and constrictive remodeling. Such ob-
servations have important implications for the identification
of patients who might benefit from further intensification of
vascular protective strategies that might mitigate their
elevated cardiovascular risk.
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